Novel Oral mTORC1/2 Inhibitor TAK-228 Has Synergistic Antitumor Effects When Combined with Paclitaxel or PI3Kα Inhibitor TAK-117 in Preclinical Bladder Cancer Models.

Hernández-Prat, Anna

Novel Oral mTORC1/2 Inhibitor TAK-228 Has Synergistic Antitumor Effects When Combined with Paclitaxel or PI3Kα Inhibitor TAK-117 in Preclinical Bladder Cancer Models. [electronic resource] - Molecular cancer research : MCR 09 2019 - 1931-1944 p. digital

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

1557-3125

10.1158/1541-7786.MCR-18-0923 doi


Administration, Oral
Animals
Antineoplastic Combined Chemotherapy Protocols--administration & dosage
Benzoxazoles--administration & dosage
Cell Line, Tumor
Cell Proliferation--drug effects
Cell Survival--drug effects
Dose-Response Relationship, Drug
Drug Synergism
Humans
Imidazoles--administration & dosage
Male
Mechanistic Target of Rapamycin Complex 1--antagonists & inhibitors
Mechanistic Target of Rapamycin Complex 2--antagonists & inhibitors
Mice
Morpholines--administration & dosage
Paclitaxel--administration & dosage
Pyridines--administration & dosage
Pyrimidines--administration & dosage
Urinary Bladder Neoplasms--drug therapy
Xenograft Model Antitumor Assays